KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Income from Continuing Operations rose 12461.96% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 281795.93%. This contributed to the annual value of $17.5 million for FY2024, which is 16961.06% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Income from Continuing Operations stood at $27.9 million, which was up 12461.96% from $59.6 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Income from Continuing Operations registered a high of $59.6 million during Q2 2025, and its lowest value of -$27.4 million during Q1 2022.
  • Its 5-year average for Income from Continuing Operations is $781473.7, with a median of -$5.7 million in 2023.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 16953.21% in 2022, then surged by 588766.99% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$22.6 million in 2021, then skyrocketed by 106.2% to $1.4 million in 2022, then tumbled by 47.39% to $737000.0 in 2023, then skyrocketed by 1843.28% to $14.3 million in 2024, then soared by 94.81% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $59.6 million for Q2 2025, and $11.4 million during Q1 2025.